112 related articles for article (PubMed ID: 3166483)
1. [The clinical usefulness of the measurement of serum sialyl SSEA-1 antigen levels in patients with gynecologic diseases: as respects the comparative effectiveness of sialyl SSEA-1 and CA125].
Kobayashi H
Nihon Sanka Fujinka Gakkai Zasshi; 1988 Jul; 40(7):828-34. PubMed ID: 3166483
[TBL] [Abstract][Full Text] [Related]
2. Clinical usefulness of sialyl SSEA-1 antigen as tumor marker for ovarian cancer as compared with CA125, CA19-9, TPA, IAP, CEA and ferritin.
Yabushita H; Sawaguchi K; Hieda S; Ogawa A; Tomatsu A; Noguchi M; Ishihara M
Nihon Sanka Fujinka Gakkai Zasshi; 1989 Feb; 41(2):217-24. PubMed ID: 2566639
[TBL] [Abstract][Full Text] [Related]
3. Clinical usefulness of serum sialyl SSEA-1 antigen levels in patients with epithelial ovarian cancer. Comparative effectiveness of sialyl SSEA-1 and CA 125.
Kobayashi H; Kawashima Y
Gynecol Obstet Invest; 1990; 30(1):52-8. PubMed ID: 1977666
[TBL] [Abstract][Full Text] [Related]
4. [The clinical significance of serum sialyl SSEA-1 antigen in obstetrical and gynecological patients].
Tanaka T; Iwasaka T; Hayashi Y; Hachisuga T; Yokoyama M; Ohkuma Y; Matsuo N; Fukuda K; Sugimori H
Nihon Gan Chiryo Gakkai Shi; 1990 Jun; 25(6):1157-61. PubMed ID: 1975831
[TBL] [Abstract][Full Text] [Related]
5. [The clinical significance of serum sialyl Tn antigen levels in patients with gynecologic tumors].
Shimizu C; Inoue M; Ogawa H; Ueda G; Tanizawa O
Nihon Sanka Fujinka Gakkai Zasshi; 1990 Nov; 42(11):1537-42. PubMed ID: 2273309
[TBL] [Abstract][Full Text] [Related]
6. [Analysis of CA 125 assay system and its diagnostic significance in gynecologic tumors].
Shimizu Y; Akagaki E; Hirota K; Kono M; Miura S; Okudaira Y
Nihon Sanka Fujinka Gakkai Zasshi; 1985 Dec; 37(12):2813-20. PubMed ID: 3866801
[TBL] [Abstract][Full Text] [Related]
7. [The clinical usefulness of serum CA72-4 analysis in patients with ovarian cancer].
Kobayashi H
Nihon Sanka Fujinka Gakkai Zasshi; 1989 May; 41(5):585-9. PubMed ID: 2754289
[TBL] [Abstract][Full Text] [Related]
8. Clinical value of sialyl Tn antigen in patients with gynecologic tumors.
Inoue M; Ogawa H; Nakanishi K; Tanizawa O; Karino K; Endo J
Obstet Gynecol; 1990 Jun; 75(6):1032-6. PubMed ID: 2342728
[TBL] [Abstract][Full Text] [Related]
9. Measurement of a monoclonal-antibody-defined antigen (90K) in the sera of patients with ovarian cancer.
Scambia G; Panici PB; Baiocchi G; Perrone L; Iacobelli S; Mancuso S
Anticancer Res; 1988; 8(4):761-4. PubMed ID: 3178164
[TBL] [Abstract][Full Text] [Related]
10. [The clinical value of sialyl SSEA-1 antigen in patients with gynecologic tumors].
Inoue M; Shimizu C; Sasagawa T; Shimizu H; Saitoh J; Ueda G; Tanizawa O; Kimura T; Kawata M; Taniguchi T
Nihon Sanka Fujinka Gakkai Zasshi; 1987 Dec; 39(12):2120-4. PubMed ID: 2892886
[TBL] [Abstract][Full Text] [Related]
11. [Clinical significance of serum sialyl Tn antigen in patients with gynecological cancer. STN Study Group].
Noda K; Shiota M; Tanizawa O; Inoue M; Tenjin Y; Sugishita T; Yakushiji M; Miyoshi T; Nozawa S; Sakuma T
Gan To Kagaku Ryoho; 1991 Jul; 18(8):1287-96. PubMed ID: 2069400
[TBL] [Abstract][Full Text] [Related]
12. Relationship of serum CA125 and lipid-associated sialic acid tumor-associated antigen levels to the disease status of patients with gynecologic malignancies.
Stratton JA; Rettenmaier MA; Phillips HB; Herabutya S; DiSaia PJ
Obstet Gynecol; 1988 Jan; 71(1):20-6. PubMed ID: 2827081
[TBL] [Abstract][Full Text] [Related]
13. [Primary research on saliva and serum CA125 assays for detecting malignant ovarian tumors].
Chen DX; Li FQ
Zhonghua Fu Chan Ke Za Zhi; 1990 Mar; 25(2):84-5, 123-4. PubMed ID: 2364796
[TBL] [Abstract][Full Text] [Related]
14. Differential diagnosis of ovarian cancer, benign ovarian tumor and endometriosis by a combination assay of serum sialyl SSEA-1 antigen and CA125 levels.
Iwanari O; Miyako J; Date Y; Nakayama S; Kijima S; Moriyama M; Takahashi K; Yoshino N; Karino K; Endoh J
Gynecol Obstet Invest; 1990; 29(1):71-4. PubMed ID: 1972127
[TBL] [Abstract][Full Text] [Related]
15. [Application of monoclonal antibody OC 125 in gynecological oncology].
Wu AR; Wang EY; Wang XX; Jia XH; Li L
Zhonghua Zhong Liu Za Zhi; 1988 Mar; 10(2):132-6. PubMed ID: 3208653
[TBL] [Abstract][Full Text] [Related]
16. [Diagnostic usefulness of stepwise discriminant analysis employing the values of CA125, TPA, IAP, CEA and ferritin in sera measured simultaneously for gynecological malignant neoplasms].
Yabushita H; Masuda T; Hattori A; Noguchi M; Ito Y; Nakanishi M; Ishihara M
Nihon Sanka Fujinka Gakkai Zasshi; 1985 Sep; 37(9):1883-92. PubMed ID: 2997349
[TBL] [Abstract][Full Text] [Related]
17. [Clinical evaluation of specificity of serum CA125 as a tumor marker of ovarian carcinoma].
Iwasaka T; Ohkuma Y; Yoshimura T; Sugimori H
Nihon Sanka Fujinka Gakkai Zasshi; 1986 Jun; 38(6):917-23. PubMed ID: 2426378
[TBL] [Abstract][Full Text] [Related]
18. Soluble epidermal growth factor receptor (sEGFR) [corrected] and cancer antigen 125 (CA125) as screening and diagnostic tests for epithelial ovarian cancer.
Baron AT; Boardman CH; Lafky JM; Rademaker A; Liu D; Fishman DA; Podratz KC; Maihle NJ
Cancer Epidemiol Biomarkers Prev; 2005 Feb; 14(2):306-18. PubMed ID: 15734951
[TBL] [Abstract][Full Text] [Related]
19. Sialyl Lewis-Xi antigen in patients with gynecologic tumors.
Inoue M; Shimizu C; Sasagawa T; Shimizu H; Saito J; Tanizawa O
Obstet Gynecol; 1989 Jan; 73(1):79-83. PubMed ID: 2909045
[TBL] [Abstract][Full Text] [Related]
20. [Usefulness of measurement of serum CA125 levels in diagnosing and treating endometriosis].
Kobayashi H; Kanayama N; Hayata T; Kawashima Y
Nihon Sanka Fujinka Gakkai Zasshi; 1987 Jul; 39(7):1054-60. PubMed ID: 3475378
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
